Compare LGVN & BNKK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGVN | BNKK |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8M | 9.4M |
| IPO Year | 2021 | 2020 |
| Metric | LGVN | BNKK |
|---|---|---|
| Price | $1.83 | $1.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | ★ $61.25 | N/A |
| AVG Volume (30 Days) | 70.5K | ★ 70.7K |
| Earning Date | 11-17-2026 | 11-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.76 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $709,000.00 | ★ $2,117,309.00 |
| Revenue This Year | $46.15 | N/A |
| Revenue Next Year | $396.46 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 201.63 |
| 52 Week Low | $0.48 | $0.90 |
| 52 Week High | $7.60 | $155.05 |
| Indicator | LGVN | BNKK |
|---|---|---|
| Relative Strength Index (RSI) | 43.56 | 38.05 |
| Support Level | $0.61 | $0.91 |
| Resistance Level | $1.86 | $1.47 |
| Average True Range (ATR) | 0.16 | 0.10 |
| MACD | 0.09 | -0.01 |
| Stochastic Oscillator | 94.00 | 26.32 |
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
Bonk Inc provides over-the-counter products and consumer products in the United States. The company offers Safety Shot Beverage, an over-the-counter drink that lowers blood alcohol content. It sells its products through direct customers, distributors, retailers, and e-commerce websites. The company generates revenue through various channels, its primary sales include nostingz suncare products which are sold through e-commerce platforms, licensing revenues from Photocil and sales of the Safety Shot Beverage. The company has two reportable segments: the dietary and energy beverage business and digital assets, consisting of investing for growth in the appreciation of the asset. It derives the majority of the revenue from the dietary and energy beverage segment.